Post-Kenvue spin-off, J&J is a pure pharmaceutical and medtech company. Revenue hit $91.7B with a 22% profit margin. The immunology pipeline alone could be worth $20B in peak sales.
Johnson & Johnson completed the Kenvue spin-off in 2023, shedding the consumer health division that had been a stable but slow-growth anchor on the portfolio. What remains is a focused pharmaceutical and medical technology company generating $91.7 billion in revenue with a product pipeline that the Research Desk considers among the deepest in the industry.
The market hasn't fully adjusted to this new reality. J&J still trades like a consumer staples-adjacent defensive play at 16x forward earnings. We think it should trade like a pharma growth company with medtech diversification — which would put it closer to 18-20x.
J&J's pharmaceutical segment generated approximately $56 billion in 2025 revenue, anchored by immunology (Stelara, Tremfya), oncology (Darzalex, Erleada, Carvykti), and neuroscience (Spravato). The segment's operating margin exceeds 35%, making it the primary profit driver.
The elephant in the room is Stelara. The blockbuster immunology drug generated roughly $20 billion at peak and began facing biosimilar competition in early 2025. Revenue erosion has been slower than feared — the transition to Tremfya as the next-generation immunology backbone has been remarkably smooth.
Tremfya, approved for psoriasis and psoriatic arthritis with inflammatory bowel disease indications in late-stage trials, has the potential to become a $10-12 billion peak revenue product. The clinical data in ulcerative colitis was, frankly, best-in-class — 67% clinical remission rates that exceeded both Stelara and competing IL-23 inhibitors.
The Research Desk has covered enough biosimilar transitions to know the pattern: the first 12 months see 20-30% erosion, then the rate slows as physicians who prefer the originator product stick with it. J&J's internal projections suggest Stelara will still generate $8-10 billion in 2027, buying Tremfya time to scale.
TickerXray Report
Get the complete Johnson & Johnson report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
J&J's MedTech segment — orthopaedics, surgery, vision, and cardiovascular — generated approximately $31 billion in 2025 revenue. The segment often gets overlooked because pharmaceutical margins are higher, but MedTech provides something pharma can't: recurring procedure-based revenue with no patent cliff risk.
The Abiomed acquisition (heart pumps) and the Shockwave Medical acquisition (intravascular lithotripsy) have strengthened the cardiovascular portfolio considerably. Shockwave's technology, which uses sonic pressure waves to break calcified arterial plaque, addresses a $7 billion market growing at 15% annually.
Robotic surgery is another growth vector. J&J's Ottava surgical robot — expected to launch in 2027 — targets the same market that Intuitive Surgical dominates with the da Vinci system. While Intuitive has a massive installed base advantage, J&J's strategy of bundling Ottava with its existing surgical instruments and orthopaedic implants creates a differentiated go-to-market approach.
MedTech margins are expanding as higher-growth, higher-margin acquisitions scale and legacy orthopaedic product lines are rationalised. We expect segment operating margins to expand from 26% to 29% by 2028.
J&J has 14 compounds in Phase 3 or registration across immunology, oncology, and neuroscience. The most promising beyond Tremfya include:
Nipocalimab — an anti-FcRn antibody targeting generalised myasthenia gravis and haemolytic disease of the fetus. Peak sales estimates range from $3-5 billion. Phase 3 data expected mid-2026.
Carvykti — the BCMA-directed CAR-T therapy for multiple myeloma. Already approved, but the move to earlier-line treatment could expand the addressable market from $5 billion to $15 billion.
Spravato — the esketamine nasal spray for treatment-resistant depression has been quietly becoming a blockbuster, with 2025 revenue approaching $2 billion. Label expansion into major depressive disorder with suicidal ideation opens additional market.
The combined peak sales potential of the late-stage pipeline exceeds $30 billion. Even applying a typical 50% probability-of-success adjustment, that's $15 billion in risk-adjusted incremental revenue — more than enough to offset the Stelara erosion.
The talc litigation, while largely resolved through the consumer health separation, continues to create headline risk. The $8.9 billion settlement plan is progressing through courts, but adverse rulings could reintroduce uncertainty.
Stelara biosimilar erosion could accelerate faster than our base case if pricing pressure from pharmacy benefit managers intensifies. And the Ottava surgical robot launch involves execution risk in a market where Intuitive Surgical has a 20-year head start.
These risks are real but, in our view, more than reflected in the current 16x forward multiple.
J&J at 16x forward earnings with a $30 billion+ pipeline, expanding MedTech margins, and a Stelara-to-Tremfya transition progressing ahead of schedule is undervalued.
Our fair value is $185-195, representing 15-25% upside from current levels. The 3.2% dividend yield — raised for 62 consecutive years — provides downside support while you wait for the pipeline catalysts to play out.
We're buyers here. The market will eventually recognise that the post-Kenvue J&J is a growth company, not a defensive stalwart. The pipeline data over the next 18 months should force that recognition.
Full forensic analysis of Johnson & Johnson
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Post-Kenvue JNJ trades at 22x earnings with a looming Stelara patent cliff worth $4-5 billion in annual revenue. The defensive premium is priced for a company that no longer exists.
SoFi's bank charter has transformed its funding costs, member economics, and competitive moat. At $18 billion market cap with $2.7 billion in revenue and 9 million members, the Research Desk breaks down why this is the most underappreciated fintech story in the market.
Honeywell trades at 33.9x earnings with a $149 billion market cap, a 1.9% dividend yield, and four distinct business segments — each arguably worth more separately than together. The breakup thesis is gaining momentum.